Company
Asgard Therapeutics
- Biotech
- Location:
- Lund, Sweden
Description
Asgard Therapeutics develops AT-108, an off-the-shelf gene therapy using direct cell reprogramming to activate professional antigen-presenting cell biology and induce immune responses for cancer immunotherapy applications.
Asgard Therapeutics is located in the Copenhagen ecosystem.
Related
Hansa BiopharmaHansa Biopharma develops immunomodulating antibody-cleaving enzyme therapies that target and inactivate IgG antibodies, inhibiting…
Ability PharmaceuticalsAbility Pharmaceuticals develops oral targeted anticancer compounds that induce selective autophagy-mediated cytotoxicity in cancer cells;…
CytuvaxCytuvax develops cancer immunotherapy and vaccines for viral and bacterial pathogens, using depot-attached cytokines as immune-stimulating…
- TolerogenixxTolerogenixx develops personalized therapies using proprietary modified immune cell technology to target immune modulation, including…
CimCureCimCure develops cancer vaccines using its proprietary iBoost conjugate technology to induce immune responses that target and destroy…
BioInvent InternationalBioInvent International discovers and develops antibody therapeutics for cancer treatment, using immunology, cancer biology, antibody…
CiMaasCiMaas develops immunotherapy products that expand and engineer natural killer (NK) cells for adoptive cell therapy and CAR‑NK applications…
CytovationCytovation develops CyPep-1, a tumor membrane-targeted immunotherapy, using peptide engineering to activate immune recognition and tumor…
MogrifyMogrify develops platform technologies for direct cellular reprogramming that analyze transcriptomic, gene regulatory, and epigenetic data…